The Axcess™ delivery
system significantly increases the absorption
of peptides, proteins and other macromolecules
across the intestinal wall when delivered
orally without any chemical modification of
the active compounds.
The Axcess™ delivery system
is based on a simple mixture of components
consisting entirely of registered pharmacopoeial
or GRAS excipients with a long history of
pharmaceutical use. The absorption enhancing
activities obtained from the formulation of
these excipients is entirely novel and forms
the basis of four international patent applications,
the first of which has been approved for grant
in Europe.
Diabetology has licensed the
exclusive rights to Axcess™ for the
formulation of its specific development and
out-licensing programs. Additionally, the
Axcess™ delivery system may allow Diabetology
to further expand its pipeline in the future
with the development of new oral therapies
for diabetes.
|
